Literature DB >> 15726593

CD5+ Epstein-Barr virus-positive intravascular large B-cell lymphoma in the uterus co-existing with huge myoma.

Noriko Yamada1, Ryo Uchida, Shin-ichi Fuchida, Akira Okano, Masashi Okamoto, Naoya Ochiai, Hirokazu Iwasa, Chihiro Shimazaki.   

Abstract

A 42-year-old female underwent hysterectomy because of a huge uterine mass. Histologically, she was diagnosed as having intravascular lymphoma co-existing with myoma uteri. Lymphoma cells were large in size and were positive for CD5, CD20, CD45, CD79a, lambda light chain, and EBV but were negative for CD3 and cyclin D1. No other organs except for the adjoining bilateral ovaries seemed to be affected by the lymphoma cells. She received the combination chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisolone) together with rituximab and has been well without definite disease progression. So far, this is the first case of CD5+ EBV+ intravascular large B-cell lymphoma (CD5+ EBV+ IVLBL) in the uterus of a patient who was incidentally diagnosed and successfully treated.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15726593     DOI: 10.1002/ajh.20288

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  2 in total

1.  Intravascular Large B-cell Lymphoma of the Bilateral Ovaries and Uterus in an Asymptomatic Patient with a t(11;22)(q23;q11) Constitutional Translocation.

Authors:  Yasuyuki Shigematsu; Motoki Matsuura; Noriko Nishimura; Naoko Tsuyama; Kengo Takeuchi; Yasuhito Terui; Nobuhiro Takeshima; Kiyohiko Hatake
Journal:  Intern Med       Date:  2016-11-01       Impact factor: 1.271

2.  EBV-positive large B-cell lymphoma with an unusual intravascular presentation and associated haemophagocytic syndrome in an HIV-positive patient: report of a case expanding the spectrum of EBV-positive immunodeficiency-associated lymphoproliferative disorders.

Authors:  Luis Veloza; Chun-Yi Tsai; Bettina Bisig; Olivier Pantet; Lorenzo Alberio; Christine Sempoux; Matthias Cavassini; Laurence de Leval
Journal:  Virchows Arch       Date:  2021-06-19       Impact factor: 4.535

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.